Clinical Trials Logo

Crohn's Disease clinical trials

View clinical trials related to Crohn's Disease.

Filter by:

NCT ID: NCT03635112 Not yet recruiting - Crohn's Disease Clinical Trials

Efficacy and Safety of TD-1473 in Crohn's Disease

DIONE
Start date: August 2018
Phase: Phase 2
Study type: Interventional

A Phase 2 study to evaluate the efficacy, safety and tolerability of TD-1473 in subjects with moderately-to-severely active Crohn's Disease with up to 36 weeks of treatment.

NCT ID: NCT03627091 Not yet recruiting - Crohn's Disease Clinical Trials

Efficacy and Safety of SHP647 as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)

Start date: November 30, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of SHP647 as maintenance treatment in participants with moderate to severe Crohn's disease (CD).

NCT ID: NCT03615690 Not yet recruiting - Crohn's Disease Clinical Trials

The Influence of Fasting and Diet on Intestinal Inflammation

Start date: September 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to see how a diet that mimics fasting effects inflammation in patients with mild to moderate ulcerative Inflammatory Bowel Disease (IBD). The diet may allow users to receive the benefits of fasting while also being able to enjoy food (the ingredients of which are GRAS (generally recognized as safe) by the Food and Drug Administration (FDA). Research on dietary interventions and IBD are very limited. Fasting mimicking diets (FMD) have been studied with support of the National Institute of Health and published in leading journals. This research investigates whether markers of inflammation decrease and/or quality of life increases after a five-day period of the fasting mimicking diet, after either one five-day cycle or three five-day cycles, and may provide rationale for its use to treat IBD.

NCT ID: NCT03599622 Recruiting - Crohn's Disease Clinical Trials

An Investigational Study of Experimental Medication BMS-986165 in Patients With Moderate to Severe Crohn's Disease

Start date: June 25, 2018
Phase: Phase 2
Study type: Interventional

This is an investigational study of experimental medication BMS-986165 in patients with moderate to severe Crohn's Disease, a chronic bowel disease that causes severe inflammation of the digestive tract.

NCT ID: NCT03566823 Recruiting - Crohn's Disease Clinical Trials

Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 306)

Start date: June 11, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of SHP647 in inducing clinical remission and endoscopic response in participants with moderate to severe Crohn's Disease.

NCT ID: NCT03566407 Recruiting - Crohn's Disease Clinical Trials

Blood and Stool Molecular Biomarkers Longitudinal Detection Study in Crohn's Disease (CD) Patients

Start date: May 4, 2018
Phase: N/A
Study type: Interventional

To evaluate the relationship between noninvasive biomarkers (patient serological markers and metagenomic analysis of stool) and disease status as determined by colonoscopy and by clinical symptoms in patients with Crohn's disease, and to evaluate whether changes in the biomarker levels over time correlate to changes in the state of patients' disease.

NCT ID: NCT03559660 Available - Crohn's Disease Clinical Trials

CUP Certolizumab Pegol (CDP-870) in Adults Suffering From Crohn's Disease (CD)

Start date: n/a
Phase:
Study type: Expanded Access

The objective of this program is to allow treating physicians to supply/continue to supply Certolizumab Pegol (CIMZIA®, CZP) to adults suffering from Crohn's Disease (CD), and who are considered not suitable for treatment, intolerant, have medical contraindications or had insufficient response with an authorized conventional therapy, including other authorized biologics.

NCT ID: NCT03559517 Recruiting - Crohn's Disease Clinical Trials

Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 305)

Start date: June 25, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of SHP647 in inducing clinical remission and endoscopic response in participants with moderate to severe Crohn's Disease.

NCT ID: NCT03524144 Enrolling by invitation - Crohn's Disease Clinical Trials

Upper Gastrointestinal Lesions in Crohn's Disease

Start date: June 1, 2017
Phase: N/A
Study type: Interventional

A cross-sectional study was performed from 2017 to 2018. Consecutive Crohn's disease patients diagnosed in the Inflammatory bowel disease center of the Sixth Affiliated Hospital of Sun Yat-sen University were recruited. All patients underwent upper gastrointestinal endoscopy and biopsy by two defined endoscopists and two pathologists, the basic information were collected at the same time, in order to assess the prevalence of upper gastrointestinal involvement, and determine the role of upper gastrointestinal endoscopy in adult Crohn's disease patients, irrespective of upper gastrointestinal symptoms.

NCT ID: NCT03478956 Recruiting - Crohn's Disease Clinical Trials

A Phase I Study Of Etrolizumab Followed By Open-Label Extension And Safety Monitoring In Pediatric Patients With Moderate To Severe Ulcerative Colitis Or Moderate To Severe Crohn's Disease

Start date: March 27, 2018
Phase: Phase 1
Study type: Interventional

This study will evaluate pharmacokinetics, pharmacodynamics and safety of etrolizumab in pediatric patients of 4 to <18 years of age with moderate to severe ulcerative colitis (UC) or with moderate to severe Crohn's disease (CD).